Filing Details
- Accession Number:
- 0000904454-10-000119
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-04-14 13:00:00
- Reporting Period:
- 2010-04-14
- Filing Date:
- 2010-04-14
- Accepted Time:
- 2010-04-14 18:23:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1296391 | Tengion Inc | TNGN | Biological Products, (No Disgnostic Substances) (2836) | 200214813 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 200406 | Johnson & Johnson | One Johnson &Amp; Johnson Plaza New Brunswick NJ 08933 | No | No | Yes | No | |
| 924020 | Johnson & Johnson Development Corp Et Al | One Johnson &Amp; Johnson Plaza New Brunswick NJ 08933 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2010-04-14 | 755,053 | $0.00 | 794,654 | No | 4 | C | Indirect | Johnson & Johnson Development Corporation |
| Common Stock | Acquisiton | 2010-04-14 | 400,000 | $5.00 | 1,194,654 | No | 4 | P | Indirect | Johnson & Johnson Development Corporation |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | Johnson & Johnson Development Corporation |
| No | 4 | P | Indirect | Johnson & Johnson Development Corporation |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Preferred Stock | Disposition | 2010-04-14 | 4,961,653 | $0.00 | 342,183 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2010-04-14 | 2,162,818 | $0.00 | 149,159 | $0.00 |
| Common Stock | Series C Preferred Stock | Disposition | 2010-04-14 | 3,823,817 | $0.00 | 263,711 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
- There is no expiration date applicable to the Series A, Series B or Series C Preferred Stock. Subject to certain conditions, immediately prior to the closing of the Issuer's initial public offering each share of Series A, Series B and Series C Preferred Stock automatically converted into shares of Common Stock on a 14.5-for-1 basis, for no additional consideration.
Billionaire Hedge Funds
